CAR-NK 003

CAR-NK 003 is an off-the-shelf, universal chimeric antigen receptor natural killer (CAR-NK) cell therapy under development by ThinkingBiomed (also known as Xinchuan Biotechnology). Derived from induced pluripotent stem cells (iPSCs), this cell therapy is engineered to express a chimeric antigen receptor targeting tumor-associated antigens. By combining the innate, MHC-independent cytotoxicity of natural killer cells with CAR-mediated specificity, CAR-NK 003 aims to target and eliminate solid tumors while minimizing the risk of graft-versus-host disease (GvHD) and cytokine release syndrome (CRS). The program is currently in the early research and discovery phase, with a development focus on thoracic, digestive tract, urinary system, and reproductive system tumors.